Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.

Basic & clinical pharmacology & toxicology - 1 May 2015

Kim Therasa, Han Nayoung, Sohn Minji, Oh Jung Mi, Lee Eui-Kyung, Ji Eunhee, Kim In-Wha

Abstract excerpt

Gene maturation differs between paediatric and adult populations, and the extrapolation of adult pharmacogenomic information to paediatrics is not always appropriate. We sought to determine the extent of paediatric pharmacogenomic trial translation into US FDA-approved labels and to evaluate needs for biomarker studies. Using FDA's Table of Genomic Biomarkers and Drugs@FDA website, 38 pharmacogenomic biomarkers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Age Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Drug Approval

Share to Pharmacogenetics

Share to Risk Assessment

Share to United States

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 25348905
DOI: 10.1111/bcpt.12341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.PMID 25348905Read ↗

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.Semantic proximity Read ↗

Clinically relevant pharmacogenomic testing in pediatric practice.Semantic proximity Read ↗

Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyondSemantic proximity Read ↗

Retrospective Review of Pharmacogenetic Testing at an Academic Children’s HospitalSemantic proximity Read ↗

Pediatric pharmacogenomics from whole-exome sequencing: developmentally appropriate interpretation in 1,159 Russian children and newbornsSemantic proximity Read ↗

Frequency and Implications of High-Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort.Semantic proximity Read ↗

Development of biomarkers to optimize pediatric patient management: what makes children different?Semantic proximity Read ↗

Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.Semantic proximity Read ↗

Identifying genomic and developmental causes of adverse drug reactions in children.Semantic proximity Read ↗

Should secondary pharmacogenomic variants be actively screened and reported when diagnostic genome-wide sequencing is performed in a child?Semantic proximity Read ↗

Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.Semantic proximity Read ↗

Adherence to International Pharmacogenomic Recommendations in Paediatric Cancer Care: A Cohort Analysis Embedded Within the MARVEL-PIC Randomised TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.